Your Top 50 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Enriqueta Felip, Byoung Chul Cho, V. Gutiérrez, Adlinda Alip, Benjamin Besse, S. Lu and 24 more
- Rank
- 22 of 3,853
- Percentile
- top 0.6%
- Where
- Annals of Oncology, 2024
- Citations
- 105
From the 2024 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.